Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
EXPENSES
General and administrative	$ 1,394,932	$ 986,484	$ 3,889,464	$ 2,047,419
Research and development	17,815	754,287	50,982	1,118,672
Credit loss expense - short-term note receivable	271,000		468,000
Total expenses	1,683,747	1,740,771	4,408,446	3,166,091
LOSS FROM OPERATIONS	(1,683,747)	(1,740,771)	(4,408,446)	(3,166,091)
OTHER EXPENSE (INCOME), NET
Gain on change in fair value of warrant liabilities	(15,974)	(493,206)	(55,199)	(359,906)
Gain on change in fair value of derivative liabilities		(10,116)		(174,613)
Gain on change in fair value of convertible debt	(37,874)		(37,874)
Interest expense	106,052	263,560	179,667	400,117
Interest income	(142,477)	(1,094)	(255,430)	(2,713)
Loss on issuance of convertible debt	91,943		91,943	358,279
Gain on voluntary conversion of convertible debt into common stock		(83,800)		(83,800)
Loss on monthly redemptions of convertible debt into common stock		61,655		208,852
Total other expense (income), net	1,670	(263,001)	(76,894)	346,216
LOSS BEFORE (BENEFIT FROM) PROVISION FOR INCOME TAXES	(1,685,417)	(1,477,770)	(4,331,553)	(3,512,307)
(BENEFIT FROM) PROVISION FOR INCOME TAXES		(1,212)	35	(2,998)
NET LOSS FROM CONTINUING OPERATIONS	(1,685,417)	(1,476,558)	(4,331,588)	(3,509,309)
DISCONTINUED OPERATIONS
Loss on disposal of discontinued operations, net of tax		(100,000)		(100,000)
GAIN (LOSS) FROM DISCONTINUED OPERATIONS		(100,000)		(100,000)
NET LOSS	(1,685,417)	(1,576,558)	(4,331,588)	(3,609,309)
Deemed dividend arising from warrant down-round provision	(1,586)		(1,586)	(60,017)
Net loss attributable to Qualigen Therapeutics, Inc	$ (1,687,003)	$ (1,576,558)	$ (4,333,174)	$ (3,669,326)
Total net loss per common share, basic	$ (1.00)	$ (10.37)		$ (27.09)
Total net loss per common share, diluted	$ (1.00)	$ (10.37)	$ (2.76)	$ (27.09)
Weighted-average number of shares outstanding, basic	1,683,881	152,065	1,570,925	135,471
Weighted-average number of shares outstanding, diluted	1,683,881	152,065	1,570,925	135,471